Izuralimab

Izuralimab is a bispecific IgG1 antibody targeting inducible T-cell costimulator (ICOS/CD278) and PD-1[1].

[1] Aghanejad A, et al. A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol. 2022 May 15;207:592-610. DOI:10.1016/j.ijbiomac.2022.03.057